Introduction

75
Targeted therapies have changed the management of many cancers types, resulting in clinical setting across many cancers, the emergence of acquired resistance is common (14) .
101
Indeed, we reported in vitro resistance to CDK2 inhibitors through selection of a polyploid 102 population in the CCNE1-amplified cell line OVCAR3 (13). Rational drug combinations are 103 a potential strategy to prevent resistance (15), and may also facilitate improvements in the 104 therapeutic window by reducing the doses of drugs required to achieve efficacy, resulting in 105 fewer side effects (16). We therefore used a high throughput drug screen to identify drug were maintained at 37°C and 5% CO 2 (vol/vol), and cultured in RPMI 1640 media containing 127 10% (vol/vol) FCS and 1% penicillin/streptomycin (P/S). Transfection and drug sensitivity 128 assays were performed in the absence of antibiotics. Cell lines resistant to dinaciclib were 129 generated utilising methods as described previously (13). Briefly, OVCAR3 cells were plated 130 in 6-well plates and treated with dinaciclib at the IC 50 dose for two 72-hour periods (media 131 removed and fresh drug added). Surviving cells were allowed to repopulate for 96 hours and 132 the process repeated once. Remaining cells were cultured in media or in the presence of drug,
133
and regularly monitored for sensitivity to dinaciclib. Six independent cell lines were 134 generated in this fashion, and designated OVCAR3-RD1 to -RD6. Author Manuscript Published OnlineFirst on September 23, 2016; DOI: 10.1158 /1078 fluorescent marker for transduction and a green (turboGFP) fluorescent marker for induction.
142
Five CDK2-specific shRNA constructs were cloned into this system (see Supplementary   143   Table S2 for sequences). For lentiviral production, HEK293T cells were transfected with 144 plasmid DNA combined with the Lenti-X packaging system (Clontech Laboratories).
145
Transfection, production of lentiviral particles and transduction of target cells was performed 146 as described by the manufacturer's protocol. Doxycycline was used to induce shRNA 147 expression, and transfection efficiency was validated by flow cytometry (FACS), and (26) were used in the analysis (N = 14, see Supplementary Table S3 ). Cell 223 lines with a log 2 copy number ratio > 0.3 over the CCNE1 locus were designated as amplified 224 (N = 9) and cell lines with a log 2 copy number ratio < 0 were designated as unamplified (N = 
Results
234
CCNE1-amplified HGSC cells are selectively sensitive to CDK2 knockdown
235
We previously demonstrated in a limited number of cell lines that CCNE1-amplified HGSC 236 cell lines are selectively sensitive to CCNE1 and CDK2 knockdown mediated by siRNA (13).
237
Following a recent analysis of ovarian cancer cell lines (26), we extended our analysis to a 238 wider number of HGSC cell lines and confirmed consistent amplicon dependent sensitivity to 239 siRNA-mediated CCNE1 and CDK2 knockdown ( Fig 1A, Supplementary Fig S1A-B) . The
240
OVCAR8 cell line has a low level gain of CCNE1 and was not sensitive to CCNE1 or CDK2 To validate the effect of CDK2 knockdown, we utilised a tetracycline-inducible shRNA 248 targeting CDK2 (Fig 1B) . Consistent with the siRNA data, inhibition of CDK2 by shRNA (Fig 2A) , 275 in contrast to the siRNA and shRNA data. Furthermore, activity in vivo was also seen in a 276 xenograft model developed from a CCNE1-unamplified cell line, CAOV3 (Fig 2A-D) . The 277 difference in amplicon dependent sensitivity between gene suppression and pharmacological 278 inhibition may be due to the broad activity of dinaciclib, which in addition to inhibiting 279 CDK2, is also active against CDK1, 5, 9 and 12 (17, 27).
280
In addition to CDK2 inhibitors, we previously identified use of bortezomib, a proteasome 281 inhibitor, as a potential therapeutic strategy for CCNE1-amplified HGSC (12). Although we 282 did not observe amplicon dependent sensitivity to dinaciclib, we investigated the interaction 283 between dinaciclib and bortezomib to see whether the two drugs would be synergistic in 284 combination. Using the Chou-Talalay methodology for drug combination studies (28), we did 285 not observe a synergistic interaction with dinaciclib and bortezomib (Fig 2E-2F 
306
Library compounds where the ratio of EC50 was less than 0.5 were selected as hits for a 307 secondary screen involving a total of 64 compounds (Supplementary Table S6-S7).
308
Compounds that appeared to have an additive effect with dinaciclib were selected as hits 309 from the secondary screen and carried forward for further testing. Table S8 ). In the OVCAR3-R1 cell 316 line, there were a number of synergistic interactions identified (Supplementary Table S8 ).
317
Non-selective BH3-mimetic agents ABT-263 and ABT-737 were synergistic in combination 318 with dinaciclib, suggestive of a class effect. This was validated further in an independently 319 derived dinaciclib-resistant cell line, OVCAR3-RD6 (Fig 3A-B, Supplementary Fig S4A-C) .
320
There was no synergistic interaction noted in the combination between dinaciclib and ABT-321 199 (Fig 3C) , a selective Bcl-2 antagonist. The combination of dinaciclib and ABT-737 Fig 3D) . Mcl-1 protein expression was not observed in the OVCAR3-RD6 cell line resistant 325 to dinaciclib (Fig 3D) . Real-time PCR demonstrated up-regulation of anti-apoptotic genes in 326 the dinaciclib and PHA533533-resistant cell lines (Fig 3E) , but down-regulation of MCL1 in dinaciclib and MK-2206, we observed that this combination was also synergistic in CCNE1-335 amplified cell lines FUOV1 and parental OVCAR3 (Fig 4A) . This effect was similarly 336 observed with another AKT inhibitor, GSK-2110183 (Fig 4B) , that was not included in the DOI: 10.1158 /1078 percentage of Annexin V positive cells measured by FACS (Fig 4C) Figure S4D) . As dinaciclib targets several CDKs in addition to CDK2 (17),
343
we used siRNA knockdown of CDK2, CDK1 or CDK9 to determine the specificity of the 344 synergistic effect of dinaciclib and MK-2206. We found that the synergy observed was 345 predominantly mediated through CDK2 (Supplementary Fig S4E) . The in vivo effect of dinaciclib and MK-2206 was assessed using xenograft models from (Fig 4D-E) , whereas there was no statistically significant effect of the (Fig 4F-G) . Taken together, the high throughput screen 360 identified a novel combination of dinaciclib and MK-2206 that appeared to be selectively with CCNE1-amplification or overexpression (Fig 5) . CDK2 was included in the analysis as a 377 control, and consistent with our previous analysis, was shown to be required in CCNE1-378 amplified cells (13). of each AKT isoform and cyclin E1 was validated with Western Blot (Fig 6A) and ( Supplementary Fig S6A) . Over-expression of AKT isoforms led to increased expression of 391 AKT downstream targets (Supplementary Fig S6B) . AKT2 and cyclin E1 over-expression 392 alone or in combination showed a trend towards increased proliferation compared to empty 393 vector alone (Fig 6B) , and AKT2 or AKT3 over-expression in combination with cyclin E1 394 showed a trend towards enhanced clonogenic colony formation in comparison to over-395 expression of cyclin E1 alone (Fig 6C) . There was a significant increase in soft agar colony 396 formation with the over-expression of AKT2 or AKT3 in combination with cyclin E1 397 compared to over-expression of cyclin E1 alone (Fig 6D) . These findings support an In addition to CDK2, dinaciclib targets CDK1, 5, 9 and 12 (17, 27 
